PL1668152T3 - Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka - Google Patents
Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutkaInfo
- Publication number
- PL1668152T3 PL1668152T3 PL04769358T PL04769358T PL1668152T3 PL 1668152 T3 PL1668152 T3 PL 1668152T3 PL 04769358 T PL04769358 T PL 04769358T PL 04769358 T PL04769358 T PL 04769358T PL 1668152 T3 PL1668152 T3 PL 1668152T3
- Authority
- PL
- Poland
- Prior art keywords
- gene expression
- identification
- breast cancer
- expression signature
- erbb2 gene
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 108700020302 erbB-2 Genes Proteins 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000009274 differential gene expression Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009452 underexpressoin Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49849703P | 2003-08-28 | 2003-08-28 | |
| EP04769358A EP1668152B1 (en) | 2003-08-28 | 2004-08-27 | Identification of an erbb2 gene expression signature in breast cancer |
| US10/928,465 US20050089899A1 (en) | 2003-08-28 | 2004-08-27 | Identification of an ERBB2 gene expression signature in breast cancers |
| PCT/IB2004/002968 WO2005021788A1 (en) | 2003-08-28 | 2004-08-27 | Identification of an erbb2 gene expression signature in breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1668152T3 true PL1668152T3 (pl) | 2009-06-30 |
Family
ID=34278600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04769358T PL1668152T3 (pl) | 2003-08-28 | 2004-08-27 | Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050089899A1 (pl) |
| EP (2) | EP1980629A3 (pl) |
| AT (1) | ATE403755T1 (pl) |
| DE (1) | DE602004015626D1 (pl) |
| ES (1) | ES2311852T3 (pl) |
| PL (1) | PL1668152T3 (pl) |
| WO (1) | WO2005021788A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050260659A1 (en) * | 2004-04-23 | 2005-11-24 | Exagen Diagnostics, Inc. | Compositions and methods for breast cancer prognosis |
| EP1907410B1 (en) | 2005-06-10 | 2012-07-04 | Saint Louis University | Methods for the selection of aptamers |
| ATE476529T1 (de) * | 2005-07-08 | 2010-08-15 | Siemens Healthcare Diagnostics | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie |
| US8709738B2 (en) * | 2006-02-27 | 2014-04-29 | Quintiles Transnational Corporation | Methods for predicting cardiac toxicity |
| US12366585B2 (en) | 2006-05-18 | 2025-07-22 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP3399450A1 (en) | 2006-05-18 | 2018-11-07 | Caris MPI, Inc. | System and method for determining individualized medical intervention for a disease state |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP2390353A1 (en) * | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD69 gene. |
| CA2695814A1 (en) * | 2007-09-07 | 2009-04-23 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in her2+ patients |
| WO2009103790A2 (en) | 2008-02-21 | 2009-08-27 | Universite Libre De Bruxelles | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications |
| US20110130296A1 (en) * | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| EP2347009A4 (en) * | 2008-10-14 | 2012-05-30 | Caris Mpi Inc | GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE |
| US20100267803A1 (en) * | 2008-11-07 | 2010-10-21 | The Research Foundation Of State University Of New York | Regulators Of Fat Metabolism As Anti-Cancer Targets |
| CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| US20110244459A1 (en) * | 2008-12-10 | 2011-10-06 | Ipsogen | Methods for identifying erbb2 alteration in tumors |
| EP2253715A1 (en) * | 2009-05-14 | 2010-11-24 | RWTH Aachen | New targets for cancer therapy and/or diagnosis |
| GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| US9040287B2 (en) | 2010-02-12 | 2015-05-26 | Mediomics, Llc | Molecular biosensors capable of signal amplification |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2016025785A1 (en) * | 2014-08-15 | 2016-02-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing cancer |
| US10274484B2 (en) | 2014-09-12 | 2019-04-30 | Mediomics Llc | Molecular biosensors with a modular design |
| JP6793451B2 (ja) * | 2014-11-14 | 2020-12-02 | キヤノンメディカルシステムズ株式会社 | 被検細胞の細胞特性を評価するための遺伝子マーカー、方法、レポーターベクター、プライマーセットおよびアッセイキット、並びに細胞特性評価装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002010436A2 (en) * | 2000-07-28 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of breast cancer |
| US20030096237A1 (en) * | 2000-08-28 | 2003-05-22 | Ulrich Certa | Determination of the ability of patients to respond to a tumor treatment |
| AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| WO2002059271A2 (en) * | 2001-01-25 | 2002-08-01 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
| WO2002103320A2 (en) * | 2001-06-18 | 2002-12-27 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
| US20030099974A1 (en) * | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
-
2004
- 2004-08-27 EP EP08007447A patent/EP1980629A3/en not_active Withdrawn
- 2004-08-27 PL PL04769358T patent/PL1668152T3/pl unknown
- 2004-08-27 AT AT04769358T patent/ATE403755T1/de not_active IP Right Cessation
- 2004-08-27 US US10/928,465 patent/US20050089899A1/en not_active Abandoned
- 2004-08-27 EP EP04769358A patent/EP1668152B1/en not_active Expired - Lifetime
- 2004-08-27 DE DE602004015626T patent/DE602004015626D1/de not_active Expired - Lifetime
- 2004-08-27 ES ES04769358T patent/ES2311852T3/es not_active Expired - Lifetime
- 2004-08-27 WO PCT/IB2004/002968 patent/WO2005021788A1/en not_active Ceased
-
2008
- 2008-09-17 US US12/212,282 patent/US20090092983A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1668152B1 (en) | 2008-08-06 |
| EP1980629A2 (en) | 2008-10-15 |
| US20090092983A1 (en) | 2009-04-09 |
| ATE403755T1 (de) | 2008-08-15 |
| ES2311852T3 (es) | 2009-02-16 |
| EP1980629A3 (en) | 2008-12-17 |
| WO2005021788A1 (en) | 2005-03-10 |
| EP1668152A1 (en) | 2006-06-14 |
| DE602004015626D1 (de) | 2008-09-18 |
| US20050089899A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1668152T3 (pl) | Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka | |
| ATE507310T1 (de) | Verfahren für den nachweis von leberkrebs, leberkrebsrisiko, risiko eines leberkrebsrezidivs,bösartigem leberkrebs und progression von leberkrebs mit der zeit anhand von methyliertem cytosin im basp1-gen | |
| WO2008154098A3 (en) | Reagents and methods for mirna expression analysis and identification of cancer biomarkers | |
| MX2007006529A (es) | Seleccionar pacientes para terapia con un inhibidor her. | |
| AU2014204426B2 (en) | Integrated nucleic acid analysis | |
| PT991421E (pt) | Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa | |
| WO2005029137A3 (en) | Fiber opticlaser-induced breakdown spectroscopy device and methods of use | |
| BRPI0607508B8 (pt) | método para detecção e/ou classificação de distúrbios proliferativos celulares colorretais ou hepatocelulares, e uso do mesmo | |
| WO2009153775A3 (en) | Methods for distinguishing between specific types of lung cancers | |
| CY1112631T1 (el) | ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2 | |
| ATE403743T1 (de) | Genetische veränderungen, die mit lungencarzinomen korrelieren | |
| ATE454468T1 (de) | Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose | |
| AU2003293141A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| WO2005014846A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| WO2004005530A3 (en) | Compositions and methods for treatment and detection of multiple cancers | |
| WO2008104985A3 (en) | Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers | |
| MXPA05004971A (es) | Pronostico para malignidad hematologica. | |
| ATE461294T1 (de) | Brustkrebsdiagnoseverfahren | |
| WO2009132928A3 (en) | Molecular markers for cancer prognosis | |
| MX2007008984A (es) | Marcadores de cancer y metodos de deteccion. | |
| CY1115258T1 (el) | Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων | |
| WO2007020522A3 (en) | Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type | |
| WO2004048546A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| ATE479778T1 (de) | Verfahren zur diagnose nicht-kleinzelliger lungenkarzinome über die trna-dihydrouridin- synthaseaktivität von urlc8 | |
| WO2022020824A3 (en) | Methods of identifying autism spectrum disorder |